The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. We enrolled 733 advanced EGFR-mutant NSCLC patients wi...

Full description

Saved in:
Bibliographic Details
Published in:Sci Rep
Main Authors: Huang, Yen-Hsiang, Tseng, Jeng-Sen, Hsu, Kuo-Hsuan, Chen, Kun-Chieh, Su, Kang-Yi, Yu, Sung-Liang, Chen, Jeremy J. W., Yang, Tsung-Ying, Chang, Gee-Chen
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8187359/
https://ncbi.nlm.nih.gov/pubmed/34103652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-91657-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items